RWJF Investigator Award in Health Policy Research: Reengineering the Value Chain of Pharmaceutical Innovation
The specific aims of the project are to: 1) identify and investigate how best to structure collective approaches to sharing resources that may help reduce the risk of pharmaceutical R&D; 2) study approaches to sharing risks for pharmaceutical R&D across public and private sectors; and 3) develop models for sharing rewards, both to ensure sufficient incentive to bring products to market and to provide fair returns on public investment. This project seeks to identify and evaluate promising, crossover approaches among neglected tropical diseases, rare diseases, antibiotics, and other therapeutic areas of public health significance that might enhance U.S. pharmaceutical innovation.
The project outcomes include: 1) a series of case studies that examine and analyze various institutional, collaborative arrangements for sharing research resource, from proprietary compounds and material reagents to licensed tools and end-products. 2) studying various public private partnership arrangements for bringing pharmaceutical products to market, 3) modeling various financing options for managing public sector and philanthropic investments to increase R&D productivity for pharmaceutical innovation.
Project Policy Impact Description
The work under this project might address 1) priority setting processes that may have application for public sector funding of pharmaceutical innovation, 2) policy directions for extending public sector science, and 3) policy guidance for developing and evaluating public private partnership and open innovation models for bringing health technologies to market.
The findings from this project have been integrated into invited presentations at several policy fora such as the Trilateral WIPO-WHO-WTO Symposium on 'Medical Innovation: Changing Business Models' (2013), World Health Summit in Berlin (2013), UAEM Panel at WTO Public Forum on 'Innovation Hubs for the 21st Century: New Approaches to University IP Management' (2014), and WHO and DNDi's Technical Consultation on 'Fostering the development and rational use of new antibiotics: How a product development partnership could promote innovation and responsible access to new antibiotics' (2014).